Modality
Degrader
MOA
MALT1i
Target
CD3
Pathway
Amyloid
HNSCCSCDPsA
Development Pipeline
Preclinical
Nov 2017
→ Jul 2030
PreclinicalCurrent
NCT05458055
1,340 pts·SCD
2017-11→2027-02·Active
NCT07180737
582 pts·PsA
2023-11→2030-07·Active
1,922 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-0510mo awayInterim· SCD
2030-07-124.3y awayInterim· PsA
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Active
Preclinical
Active
Catalysts
Interim
2027-02-05 · 10mo away
SCD
Interim
2030-07-12 · 4.3y away
PsA
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05458055 | Preclinical | SCD | Active | 1340 | Mayo |
| NCT07180737 | Preclinical | PsA | Active | 582 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |